首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷癌症個人化醫學分子呈像/呈影劑核子醫學

市場調查報告書

商品編碼

1316304

全球 Theranostics 市場 - 2023-2030 年

Global Theranostics Market - 2023-2030

出版日期: 2023年07月27日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概述

全球治療儀市場規模在2022 年達到18 億美元，預計到2030 年將實現利潤豐厚的成長，達到42 億美元。在預測期內（2023-2030 年），全球治療儀市場將呈現11.3% 的複合年成長率。

Theranostics 是治療和診斷兩個術語的組合。治療學是指使用一種放射性藥物進行識別（診斷），並使用第二種放射性藥物進行治療，以治療主要腫瘤和任何轉移性腫瘤。這些檢測主要用於各種形式的癌症。治療學的主要關注點是藉助更加個性化和精確的方法，提供以患者為中心的護理。

全球治療學市場的最新趨勢包括：奈米藥物因其成像功能而被廣泛採用，並被整合成一個單一的實體，即奈米otheranostics，它將診斷和藥物治療結合在一起。此外，人們對使用聚集誘導發光發光劑進行細菌治療的興趣也在不斷成長。

製藥公司、研究機構和醫療保健提供商對該市場的投資和合作不斷增加。這主要得益於對提供個性化和靶向治療的治療儀需求的不斷成長。此外，在整個預測期內，治療儀領域正在進行的研究工作、臨床試驗數量的增加以及旨在提高認知和促進進步的會議數量的增加預計將成為主要的推動因素。

市場動態

用於治療癌症的放射性核素治療技術研究會議的增加將推動全球治療技術市場的成長

根據《2022 年戈登研究會議》，會議將探討放射性核素治療癌症的最新進展和影響。會議旨在促進來自學術界、私人診所和行業等不同領域的科學家、醫生和專家等傑出演講者之間的正式和非正式互動與合作。會議的主要科學目標是應對放射性核素治療學的相關挑戰，鼓勵在癌症研究方面取得重大突破。

會議形式獨特，其特點是規模小、環境幽靜、數據未公開發表、討論時間充裕，為有意義的互動與合作提供了難得的機會，很可能對該領域產生重大而持久的影響。利用放射性核素成像和治療的精準腫瘤學正處於創新和顯著成長的變革階段，因此本次會議意義尤為重大。

它提供了比以往任何時候都更精確的診斷和個性化有效抗腫瘤治療的潛力。此外，越來越多的大型製藥公司參與進來，放射治療領域也湧現出50 多家新公司，這些都證明了這一點。

此外，利用BETA、α或γ放射性核素治療癌症的臨床試驗數量也在迅速增加。本次會議的時機至關重要，因為它恰逢基於放射性核素的精準腫瘤學即將取得重大進展的關鍵時刻，標誌著該領域的範式轉變和前所未有的進步。因此，由於上述因素，市場將在預測期內得到推動。

美國FDA 批准的癌症治療方案越來越多，將推動全球血流顯像技術市場的成長

2022 年11 月29 日，Clarity Pharmaceuticals 公司獲得美國食品及藥物管理局（FDA）批准，開展治療前列腺癌的SAR-Bombesin 臨床試驗。前列腺癌是導致全球癌症相關死亡的第五大原因，也是第二大最常見的男性癌症。據美國國家癌症研究所（NCI）稱，僅在美國，每年就有約268,490 例前列腺癌病例報告，導致約34,500 人死亡。

SAR-Bombesin 是一種放射性藥物，旨在靶向存在於各類癌症中的特定細胞表面受體。新聞稿強調，胃泌素釋放肽受體（GRPr）可在75%-100%的前列腺癌中發現。

SAR-Bombesin 複合物具有多重功效。它的SAR 成分（也稱為sarcophagine）是一種螯合劑，能安全地封裝銅同位素，防止其洩漏到體內。該公司稱，SAR-Bombesin 是一種靶向銅治療藥物（TCT），可將銅-64 同位素（Cu-64 或64Cu）用於成像，將銅-67 同位素（Cu-67 或67Cu）用於治療。

同樣，2022 年3 月23 日，諾華公司的PluvictoTM（镥-Lu 177 vipivotide tetraxetan）（以前稱為177Lu-PSMA-617）獲得了美國食品及藥物管理局的批准。這項批准允許Pluvicto 用於治療患有前列腺特異性膜抗原陽性（PSMA 陽性）腫瘤並已擴散到身體其他部位的轉移性抗性前列腺癌（mCRPC）成人患者。這些患者已經接受了其他抗癌治療，如雄激素受體通路抑制和基於類固醇的化療。

此外，FDA 還批准了Locametz（鎵Ga 68 戈氮卓肽注射液的製備試劑盒）。經過放射性標記後，這種成像劑可用於mCRPC成年患者，通過正電子發射斷層掃描（PET）確定PSMA陽性病灶。

通過使用鎵-68標記的洛卡麥茨，醫生可以檢測到表達PSMA生物標記物的腫瘤病灶，並確定腫瘤在體內（包括軟組織、淋巴結或骨骼）的擴散情況。這有助於確定符合使用普盧維特進行靶向治療的患者。 PSMA在80%以上的前列腺癌患者中高度表達，是評估轉移性前列腺癌進展的重要生物標記物。

治療技術的高成本將阻礙全球治療技術市場的成長

利用放射性藥物的治療學領域在改善癌症診斷和治療方面前景廣闊。然而，一些最有效的治療藥物依賴於稀有的同位素，這些同位素很難獲得，而且將其轉化為能夠靶向消除癌細胞的藥物成本高昂。雖然癌症治療的進步指日可待，但也不可避免地伴隨著高昂的代價。

例如，用於癌症診斷的镥177療法的費用因國家、醫院和主治醫生而異。镥177 治療的平均費用約為每個療程10 000 美元，病人可能需要接受三至四個療程的治療。

同樣，在印度，Lu177 PSMA 治療的估計費用通常從5000 美元起，最高可達6000 美元。此外，在德國，專科醫院使用镥177 進行PSMA 治療的費用在8000-16000 歐元之間，其中包括初始臨床和實驗室檢查、PSMA 治療本身、後續檢查和住院費用。因此，由於上述因素，市場在預測期內將受到阻礙。

COVID-19 影響分析

受COVID-19 爆發的影響，治療儀市場在預測期內將面臨初步的挑戰和衰退。全國範圍的封鎖和限制導致診斷服務中斷和手術取消，影響了對治療儀的需求。

疫情尤其影響了腫瘤和心血管疾病患者的治療，因為這些患者因年齡和合併症而患重病的風險較高。疫情爆發的程度和實施的限制因地區而異，對慢性病患者的影響也不盡相同。

在德國等國家，為防止對醫療系統造成壓力，實施了公共封鎖和非緊急醫療服務限制。由於COVID-19 的影響，醫療保健行業的供應鍊和需求都受到了乾擾。

由於公眾對去醫院就診的恐懼減緩了對治療程序的需求，這種程序常用於腫瘤和與腫瘤相關的疾病，因此可幫助降低感染毒性（包括COVID-19）的治療程序也受到了影響。不過，隨著疫情得到控制，人們適應了新的生活方式，醫學專家們一直在研究這種病毒，並探索在治療中使用治療儀。

COVID-19 大流行對全球的影響要求我們採取更有效的措施來減少病毒的傳播，並開發高效的治療藥物。包括冠狀病毒在內的病毒具有高度異質性，這給開發有效的抗病毒藥物帶來了巨大挑戰。病毒的高變異率會對病毒檢測、藥物和疫苗開發的有效性產生負面影響，甚至導致耐藥性。然而，治療學領域提供了前景廣闊的解決方案。

此外，奈米機器人的使用可提供即時的病毒防護，為治療包括COVID-19 在內的各種疾病的療法的重大進展提供了可能性。此外，基於奈米技術的方法不僅徹底改變了傳統的消毒程序，還為加速監測冠狀病毒及其相關生物標記物提供了分析工具。這些方法有助於將藥物輸送到呼吸系統或其他受影響的器官。

俄烏衝突分析

俄烏戰爭對全球地緣政治格局的各個方面都產生了影響，包括對治療儀市場的潛在影響。在政治不穩定的情況下，俄羅斯、烏克蘭和其他國家的機構之間的研發合作可能面臨挑戰。科研合作的中斷可能會減緩治療儀研究的進展，阻礙新技術和新療法的開發。

持續的衝突可能會給俄羅斯和烏克蘭的醫療保健系統帶來額外的壓力。由於資源被轉用於解決衝突造成的緊急醫療需求，治療技術研究、基礎設施和實施方面的投資和優先事項可能會受到影響。因此，考慮到上述因素，可以說戰爭對治療儀市場的影響不大。

GE Healthcare
- 公司概況
- 產品組合和說明
- 財務概況
- 主要發展
Jubilant Pharmova Limited (Jubilant Pharma Limited)
Theragnostics Ltd.
NuView Life Sciences
Lantheus Holdings, Inc.
CapVest Limited (Curium Pharma)
Clarity Pharmaceuticals
Cardinal Health, LLC
Advanced Accelerator Applications
ITM Isotopen Technologien Munchen AG

第14 章：附錄

簡介目錄

Product Code: BT1187

Market Overview

The global theranostics market reached US$ 1.8 billion in 2022 and is expected to witness lucrative growth by reaching up to US$ 4.2 billion by 2030. The global theranostics market is to exhibit a CAGR of 11.3% during the forecast period (2023-2030).

Theranostics is a combination of the terms therapeutics and diagnostics. Theranostics is the term used to describe the combination of using one radioactive drug to identify (diagnose) and a second radioactive drug to deliver therapy to treat the main tumor and any metastatic tumors. These tests are mainly used for various forms of cancers. The key concern in therapeutics involves patient-centric care with the help of a more personalized and precise approach.

Recent trends in the global theranostics market include the widespread adoption of nanomedicines for their imaging capabilities and their integration into a single entity known as nanotheranostics, which combines diagnosis and drug therapy. Additionally, there is a growing interest in using aggregation-induced emissive luminogens for bacterial theranostics.

The market is witnessing rising investment and collaborations among pharmaceutical companies, research institutions, and healthcare providers. This is driven by the increasing demand for theranostics, which offer personalized and targeted treatments. Furthermore, ongoing research endeavors in the field of theranostics, a rise in the number of clinical trials, and the increasing number of conferences aimed at raising awareness and promoting advancements are anticipated to be key driving factors throughout the forecast period.

Market Dynamics

Increasing Research Conferences in Radionuclide Theranostics for the Management of Cancer are to Drive Global Theranostics Market Growth

According to Gordon Research Conference 2022, it will explore the latest advancements and impact of Radionuclide Theranostics in the management of cancer patients. It aims to facilitate formal and informal interactions and collaborations among a distinguished group of speakers, including scientists, physicians, and experts from various sectors such as academia, private practice, and industry. The primary scientific objective of the conference is to address the challenges associated with radionuclide theranostics and encourage significant breakthroughs in cancer research.

The unique format of the conference, characterized by its small size, secluded setting, unpublished data, and ample time for discussion, provides an exceptional opportunity for meaningful interactions and collaborations that are likely to have a substantial and enduring impact on the field. This gathering is particularly significant as precision oncology utilizing radionuclide-based imaging and therapy is experiencing a transformative phase of innovation and remarkable growth.

It offers the potential for more precise diagnostics and personalized and effective anti-tumor treatments than ever before. Moreover, this is evident from the increasing participation of major pharmaceutical companies and the emergence of over 50 new players in the field of radiotheranostics.

Furthermore, the number of clinical trials utilizing beta, alpha, or gamma-emitting radionuclides in cancer treatment is rapidly expanding. The timing of this conference is crucial, as it coincides with the pivotal moment when radionuclide-based precision oncology is poised for significant advancements, signifying a paradigm shift in the field and unprecedented progress. Thus, owing to the above factors, the market is to drive over the forecast period.

Increasing FDA Approvals in Cancer are to Drive Global Theranostics Market Growth

On November 29, 2022, Clarity Pharmaceuticals received approval from the FDA to conduct clinical trials with SAR-Bombesin, a theranostic agent, for the treatment of prostate cancer. Prostate cancer ranks as the fifth leading cause of cancer-related deaths worldwide and is the second most commonly diagnosed cancer in men. In the United States alone, approximately 268,490 cases of prostate cancer are reported annually, resulting in about 34,500 deaths, according to the NCI.

SAR-Bombesin is a radiopharmaceutical designed to target specific cell surface receptors present in various types of cancer. The press release highlights that gastrin-releasing peptide receptors (GRPr) can be found in 75-100% of prostate cancers.

The SAR-Bombesin compound offers multiple benefits. Its SAR component, also known as sarcophagine, acts as a chelator that securely encapsulates copper isotopes, preventing any leakage into the body. The company states SAR-Bombesin is a Targeted Copper Theranostic (TCT) that can utilize copper-64 isotopes (Cu-64 or 64Cu) for imaging purposes and copper-67 isotopes (Cu-67 or 67Cu) for therapeutic applications.

Similarly, on March 23, 2022, Novartis received FDA approval for PluvictoTM (lutetium Lu 177 vipivotide tetraxetan), previously known as 177Lu-PSMA-617. This approval allows Pluvicto to be used in the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have prostate-specific membrane antigen-positive (PSMA-positive) tumors that have spread to other parts of the body. These patients have already undergone other anticancer treatments such as androgen receptor pathway inhibition and taxane-based chemotherapy.

Additionally, the FDA has approved Locametz (kit for the preparation of gallium Ga 68 gozetotide injection). After radiolabeling, this imaging agent can be used in adult patients with mCRPC to identify PSMA-positive lesions through positron emission tomography (PET) scans.

By using Gallium-68 labeled Locametz, physicians can detect tumor lesions expressing the PSMA biomarker and determine the spread of tumors in the body, including soft tissue, lymph nodes, or bone. This helps identify patients eligible for targeted treatment with Pluvicto. PSMA is highly expressed in over 80 percent of patients with prostate cancer, making it a crucial biomarker for assessing the progression of metastatic prostate cancer.

High Cost of Theranostics is to Hamper Global Theranostics Market Growth

The field of theranostics, which utilizes radiopharmaceuticals, holds great promise for improving cancer diagnosis and treatment. However, some of the most effective theranostic agents rely on rare isotopes that are challenging to obtain and costly to convert into drugs capable of targeting and eliminating cancer cells. While advancements in cancer care are shortly, they will inevitably come with a high price tag.

For instance, the cost of Lutetium-177 therapy for cancer diagnosis varies depending on the country, hospital, and treating doctor. The average cost of Lutetium-177 therapy is around $10,000 per course, and a patient may undergo three to four courses.

Similarly, in India, the estimated cost of Lu177 PSMA Therapy usually starts at $5000 and may go up to $6000. Also, in Germany, the cost of PSMA therapy with Lutetium 177 in specialized hospitals ranges between 8000-16,000 euros, which covers the cost of the initial clinical and laboratory examination, the PSMA therapy itself, the follow-up examinations, and the hospital stay. Thus, owing to the above factors, the market is to hamper over the forecast period.

COVID-19 Impact Analysis

The theranostics market is to face initial challenges and decline during the forecast period due to the impact of the COVID-19 outbreak. Nationwide lockdowns and restrictions have led to disrupted diagnostic services and canceled procedures, affecting the demand for theranostics.

The pandemic has particularly affected the care of patients with oncology and cardiovascular diseases, as they are at a higher risk of severe illness due to their age and comorbidities. The extent of the outbreak and the restrictions imposed vary across regions, influencing individuals with chronic diseases differently.

In countries like Germany, efforts were made to prevent strain on the healthcare system, but public lockdowns and limited access to non-urgent medical services were implemented. The healthcare industry has experienced disruptions in supply chains and demand due to COVID-19.

Theranostics, which can assist in reducing the virulence of infections, including COVID-19, have been impacted as the fear of hospital visits among the public has slowed down the demand for theranostic procedures, which are commonly used in oncology and tumor-related conditions. However, as the pandemic is brought under control and people adapt to the new lifestyle, medical experts have been studying the virus and exploring the use of theranostics in its treatment.

The global impact of the COVID-19 pandemic necessitates the implementation of more effective measures to mitigate the spread of the virus and develop efficient theranostic agents. The high heterogeneity of viruses, including the coronavirus, poses a significant challenge in developing effective antiviral agents. The virus's high mutation rates can negatively impact virus detection, the efficacy of drug and vaccine development, and even lead to drug resistance. However, the field of theranostics offers promising solutions.

Additionally, the use of nanorobots provides real-time protection against viruses, opening up possibilities for significant advancements in theranostics for various diseases, including COVID-19. Furthermore, nanotechnology-based approaches not only revolutionize traditional disinfection procedures but also offer analytical tools for accelerated monitoring of the coronavirus and its associated biomarkers. These approaches can facilitate drug delivery to the respiratory system or other affected organs.

Russia-Ukraine Conflict Analysis

The Russian-Ukraine war has had an impact on various aspects of the global geopolitical landscape, including potential implications for the theranostics market. In the face of political instability, research and development collaborations between institutions in Russia, Ukraine, and other countries may face challenges. Disruptions in scientific collaborations could slow down the progress of theranostic research and hinder the development of new technologies and treatments.

The ongoing conflict may place additional strain on the healthcare systems in both Russia and Ukraine. As resources are redirected towards addressing immediate healthcare needs arising from the conflict, investments, and priorities for theranostics research, infrastructure, and implementation may be affected. Therefore, taking into account the factors mentioned earlier, it can be stated that the theranostics market experienced a moderate impact as a result of the war.

Segment Analysis

The global theranostics market is segmented based on application, radioisotopes, end user, and region.

Oncology from the Application Segment Account for 57.9% of the Market Share Owing to the Increasing Prevalence of Cancer, Growing Theranostics Gordon Research Conferences

According to Pan American Health Organization Report 2023, globally, there were an estimated 20 million new cases of cancer and 10 million deaths from cancer. The cancer burden will increase by approximately 60% over the next two decades, further straining health systems, people, and communities. The predicted global burden will increase to about 30 million new cancer cases by 2040, with the greatest increases occurring in low- and middle-income countries.

In the Americas region the, number of people to be diagnosed with cancer will increase by 57%, to approximately 6.23 million people are predicted to be diagnosed with cancer by 2040, if no further action is taken to prevent and control cancer.

Additionally, On June 23, 2023, Cardinal Health Nuclear & Precision Health Solutions (NPHS) will be showcasing their radiotherapies and theranostics readiness at the annual meeting of the Society of Nuclear Medicine & Molecular Imaging (SNMMI) in booth #2041.

Attendees at the Cardinal Health NPHS booth will have the opportunity to learn about the company's reliable access to radiopharmaceuticals and solutions that contribute to safe, efficient, and high-quality patient care. The booth will feature demonstrations of the Nuctrac theranostic module and offer "Ask an Expert" sessions on theranostics and USP <825>, which sets requirements for the preparation, compounding, dispensing, and repackaging of radiopharmaceuticals.

At SNMMI 2023, visitors to Booth #2041 will discover how Cardinal Health NPHS is advancing nuclear medicine through its expertise and comprehensive range of products and services. They are dedicated to improving patient care by enhancing productivity, efficiency, and theranostics practice management solutions. Thus, owing to the above factors, the market segment is to hold the largest market share over the forecast period.

Geographical Analysis

North America Accounted for Approximately 43.9% of the Market Share Owing to the Increasing Prevalence of Cancer, Rising FDA Approvals, and Growing Research in Theranostics

The increasing prevalence of cancer, rising FDA approvals, and growing research in theranostics are some factors due to which the market is to boost in the forecast period. For instance, on March 23, 2022, the U.S. FDA approved 177Lu-PSMA-617, a radiopharmaceutical therapy to treat metastatic castration-resistant prostate cancer (mCRPC). In mCRPC patients treated with 177Lu-PSMA-617, the therapy has been shown to reduce the risk of death by 38% and the risk of progression by 60%. It was developed after years of extensive research.

Furthermore, UChicago Medicine is a leader in the development and administration of theranostic procedures. They are actively researching to expand this promising treatment option for other types of cancer. UChicago Medicine is the only hospital in Illinois to have a medical cyclotron, which is a powerful machine capable of manufacturing new kinds of radiotracers. The research team partners with experts at Argonne National Laboratory, an internationally renowned facility that has provided instrumental research on using radiation to treat cancer.

Sophisticated radiotracers consisting of a biological component engineered to latch on to cancer cells and interchangeable radioactive isotopes that can make those cells visible on a PET scan are providing physicians with more tools to fight certain cancers. Theranostics is a one-two punch against cancer that involves finding cancer cells anywhere in the body and delivering targeted radiation to kill those cells. Thus, owing to the above factors, the North American region is to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the market include: GE Healthcare, Jubilant Pharmova Limited (Jubilant Pharma Limited), Theragnostics Ltd., NuView Life Sciences, Lantheus Holdings, Inc., CapVest Limited (Curium Pharma), Clarity Pharmaceuticals, Cardinal Health, LLC, Advanced Accelerator Applications, and ITM Isotopen Technologien Munchen AG among others.

Why Purchase the Report?

To visualize the global theranostics market segmentation based on application, radioisotopes, end-user, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of theranostics market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global theranostics market report would provide approximately 61 tables, 63 figures, and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Application
3.2. Snippet by Radioisotopes
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Research Conferences in Radionuclide Theranostics for the Management of Cancer
  - 4.1.1.2. Increasing FDA Approvals in Cancer
- 4.1.2. Restraints
  - 4.1.2.1. High Cost of Theranostics Diagnostic
- 4.1.3. Opportunity
  - 4.1.3.1. Fast-Growing Field of Photo-Driven Theranostics
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Oncology*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Neurological Disorder
8.4. Cardiovascular Disease
8.5. Others

9. By Radioisotopes

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotopes
- 9.1.2. Market Attractiveness Index, By Radioisotopes
9.2. Technetium-99*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Gallium-68
9.4. Lutetium (Lu) 177
9.5. Iodine-131
9.6. Zirconium-89
9.7. Y-90
9.8. Others

10. By End User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Cancer Research Institutes
10.4. Diagnostic Centers
10.5. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
- 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.2.6.1. U.S.
  - 11.2.6.2. Canada
  - 11.2.6.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
- 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.3.6.1. Germany
  - 11.3.6.2. U.K.
  - 11.3.6.3. France
  - 11.3.6.4. Italy
  - 11.3.6.5. Spain
  - 11.3.6.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
- 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.4.6.1. Brazil
  - 11.4.6.2. Argentina
  - 11.4.6.3. Rest of South America
11.5. Asia Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
- 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.5.6.1. China
  - 11.5.6.2. India
  - 11.5.6.3. Japan
  - 11.5.6.4. Australia
  - 11.5.6.5. Rest of Asia Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
- 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Product Benchmarking
12.3. Company Share Analysis
12.4. Key Developments and Strategies

13. Company Profiles

13.1. GE Healthcare*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Jubilant Pharmova Limited (Jubilant Pharma Limited)
13.3. Theragnostics Ltd.
13.4. NuView Life Sciences
13.5. Lantheus Holdings, Inc.
13.6. CapVest Limited (Curium Pharma)
13.7. Clarity Pharmaceuticals
13.8. Cardinal Health, LLC
13.9. Advanced Accelerator Applications
13.10. ITM Isotopen Technologien Munchen AG

LIST NOT EXHAUSTIVE